Holland & Knight Advises DifGen Pharmaceuticals on Acquisition of Manufacturing Facility in South Florida

MIAMI (March 18, 2024) – Holland & Knight advised DifGen Pharmaceuticals LLC on its all-cash purchase, through its subsidiary Aveva Drug Delivery Systems Inc., of the operating and manufacturing assets of a U.S. Food and Drug Administration (FDA)-registered manufacturing facility owned by New Vision Pharmaceuticals and located in Tamarac, Florida. The transaction was closed on March 18.

The facility has state-of-the-art manufacturing capability to handle solutions/suspension/emulsions through blow-fill-seal, form-fill-seal technology and traditional filling of liquid and semi-solid products in a variety of dosage forms, including stick packs and unit-dose cups.

DifGen, based in Princeton, New Jersey, is a global pharmaceutical company with a primary focus on developing and manufacturing complex, high-barrier-to-entry generics and specialty pharmaceutical products that would help increase accessibility to high-quality medication, thereby leading to the creation of next generation healthy communities.

Holland & Knight served as transaction and regulatory counsel to DifGen. The team was led by Partners Maria Currier, Emma Solaun and Gavin Williams, along with Associates Sara Klock, Nathan Gardner, Oliver Peglow and Caroline Barber. They were assisted by Partners Eddie Williams, Larry Curtin and Christine Gay.

More information on the transaction can be found here.

Holland & Knight regularly ranks among the leading M&A and private equity law firms in reputable, benchmarking league tables published by Bloomberg, LSEG (formerly Refinitiv), Mergermarket, PitchBook and The Deal. In 2023, the firm ranked among the top 5 most active law firms in the U.S. and top 10 globally for its work in the space. Through the HK Deal Flow℠ program, Holland & Knight facilitates deal leads for clients and prospective clients by matching acquisition or capital raising opportunities with buyers and investors.